Skip to main
BNGO

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics is set to see significant revenue growth in the coming years, driven by increased utilization of its optical genome mapping (OGM) technology across multiple industries including hematologic malignancies, constitutional genetics, and cell and gene therapy quality control. With a strong cash position and signs of expanding utilization in new regions, the company is well positioned to capitalize on its innovative technology. Risks include potential lower-than-projected market uptake and utilization, as well as potential need for additional capital. We reiterate a Buy rating and adjust our 12-month price target to $6 from $7 per share, using a conservative EV/Revenue of 1.5x for projected sales of $2.87 per share for FY2026.

Bears say

Bionano Genomics is showcasing its growing body of research and scaling high-volume solutions at the sold-out 2026 Bionano Symposium, highlighting OGM's ability to detect complex genomic rearrangements that traditional methods often miss. This is supported by published studies showing high concordance and superior detection of structural variants in various types of cancer, indicating potential for a broader application beyond liquid tumors. However, the company's financials show a cash runway only until 2Q26 and potential need for additional capital in the next 12 months. Despite the recent establishment of Category I CPT codes and multiple publications highlighting OGM's utility, the future growth and widespread adoption of OGM remains uncertain, leading to a negative outlook for the stock.

Bionano Genomics (BNGO) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Bionano Genomics (BNGO) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.